文献速递白血病

年轻 favorable-risk AML 巩固治疗中中剂量阿糖胞苷较高剂量复发风险更高:多中心回顾性分析

High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature.
PubMed 文献 · Br J Haematol · 2021-04-11

该研究回顾性分析 80 例接受 7+3 诱导的年轻(<60 岁)favorable-risk AML 患者,比较高剂量阿糖胞苷(HIDAC)与中剂量阿糖胞苷(IDAC)巩固的临床影响。

要点

  • 年轻 favorable-risk AML 经 7+3 诱导后,IDAC 巩固的 3 年复发风险显著高于 HIDAC。
  • 研究提示 HIDAC 应作为该人群单药阿糖胞苷巩固的首选剂量。

核心结论

  • 在年轻 favorable-risk AML 患者 7+3 诱导后,HIDAC 较 IDAC 单药巩固显著降低 3 年复发风险。

研究设计与样本

  • 回顾性多中心分析,纳入 80 例年轻(<60 岁)favorable-risk AML 患者,51 例接受 HIDAC、29 例接受 IDAC 巩固。

临床怎么用

  • 对接受 7+3 诱导的年轻 favorable-risk AML 患者,巩固阶段宜优先选择 HIDAC 而非 IDAC。

局限性

  • 本研究为回顾性分析,样本量较小(共 80 例),且为单次实践变更前后的比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Following the 2017 European LeukemiaNet (ELN) guidelines, we changed our practice from using high-dose cytarabine (HIDAC-3 g/m2 q12h-D1,3,5) to intermediate-dose cytarabine (IDAC-1·5 g/m2 q12h-D1,3,5/D1-3) for consolidation in young(<60 years) favourable-risk acute myeloid leukaemia (AML) patients. We assessed the clinical impact of this practice change. Of 80 patients, 51 received HIDAC prior to the protocol change, and subsequently, 29 received IDAC. The three-year risk of relapse was significantly higher with IDAC [61%; 95% confidence interval (CI) 40-82] compared with HIDAC (22%; 10-34), P < 0·01. Our findings suggest HIDAC, rather than IDAC, is the preferred dose for single-agent cytarabine consolidation in young, favourable-risk AML following 7+3 induction.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Kolla BC, Halim NAA, Cao Q, et al. High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature. Br J Haematol. 2021. PMID: 33843048. doi:10.1111/bjh.17462

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。